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SUMMARY.-Hyperimmune heterologous serum produced in sheep against
mouse Ehrlich ascites tumour cells was absorbed with normal mouse tissue
and fractionated by DEAE column chromatography into IgGl and IgG2 frac-
tions. In vitro cytotoxicity test showed that sheep anti-Ehrlich ascites tumour
IgGl fraction was cytotoxic to 51Cr labelled tumour cells whereas IgG2 had no
cytotoxic effect. Pretreatment of the tumour cells with the non-cytotoxic
IgG2 fraction slightly inhibited the cytotoxic action of IgGl in vitro.
When EAT cells were coated with either IgGl or IgG2 by preincubation
in vitro before injecting intraperitoneally into mice, both fractions protected the
animals againsttumourgrowth. InjectionofIgG2 andIgGl fractionsseparately,
one before and the other after the injection of EAT cells, resulted in partial
protection only. The difference encountered between the in vitro and in vivo
findings could be attributed to the host defence mechanisms involved in the in
vivo test system.
ANTIBODY fractions, particularly the immunoglobulin G subclasses IgGI
and IgG2, have been of special interest to tumour immunologists in recent years
due to their cytotoxic and enhancing effects on tumour growth. These two types
of antibodies differ in electrophoretic mobility and biological properties (Bloch,
1965). In mice, the enhancing activity was found to migrate in the faster frac-
tions on electrophoresis, the cytotoxic activity in the slowerfractions (Voisin et al.,
1966). Experimental evidence also indicated that the biological properties of
IgGI and IgG2 differ in different species. Guinea-pig IgG2 antibodies have the
distinct property of fixing complement in the presence of antigen and thereby
causing in vitro cytotoxic activities whereas guinea-pig IgGI do not fix complement
(Ovary et al., 1963). Takasugi and Hildemann (1969) showed that when Sal
sarcoma originally induced in A strain mice is injected into A.BY allogeneic host
IgGI rejected the tumour whereas IgG2 led to enhancement of tumour growth.
Broder and Whitehouse (1968) injected guinea-pigs with mouse Ehrlich ascites
tumour cells and found that the growth of these cells as tumour xenografts was
inhibited by IgG2 and enhanced by the F(ab)2 fragment. Feinstein and Hobart
(1969) investigated the complement fixing activity of sheep IgG antibodies and
found that IgGI contained high complement fixing activities whereas IgG2 has
no complement fixing activity. These findings suggested that this is obviously a
field which deserves further attention.
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Ehrlich ascites tumour (EAT) is transplantable in a number of mouse strains
and produces progressive growth ofthe tumour to the death ofthe host. It may
be argued that there is an obliteration or decrease ofantigenic expression in EAT
cells so that they are able to survive and grow in a number of mouse strains.
However, that EAT is not devoid ofits tumour-specific antigens and that specific
immunity to EAT does exist have been demonstrated by several workers using
various methods. These involve repeatedtapping ofthe ascites fluid (Apffel et at.,
1966b) pretreatment of EAT with X-irradiation (McKee et al., 1959) and iodo-
acetate (Apffel et al., 1966a) or immunization ofmice using a hamster/EAT hybrid
cell line (Watkins and Chen, 1969). However, our attempt to induce circulating
anti-tumour antibodies and resistance to tumour growth in CBA and Herston
white mice by the iodoacetate method was not successful (Wang and Halliday,
1967). The failure to induce immunity to EAT by the iodoacetate method which
has been successfully employed by Apffel and co-workers (1966a) may have depen-
ded on the different strains of mice used as well as on the recent natural history
of the EAT studied.
In the present work, in order to potentiate the formation of anti-EAT anti-
bodies, a heterologous antiserum has been prepared in sheep. This approach has
allowed the possibility of further investigation into the effect of the anti-EAT
antiserum fractions on EAT cells by both in vitro and in vivo methods.
MATERBA.L AND METHODS
Tumour
Ehrlich ascites tumour was obtained from Dr. K. F. Gregory ofthisUniversity.
The tumour line was maintained by weekly serial passage in Swiss mice of the
Connaught Strain.
Immunization procedure
Seven days after intraperitoneal implantation into adult Swiss mice, EAT cells
were collected in heparin and diluted with physiological saline. Two sheep
(Oxford breed) were each injected intramuscularly with 4 x 108 EAT cells in
5 ml. of suspending medium at 2 weeks intervals for 3 months. The sheep were
bled before each subsequent immunization and the sera from each immunization
were storedseparately. Atotalof7 immunizations were carried outoneachsheep.
Absorption of antisera
Antisera were absorbed with I volume of mouse normal tissue homogenate for
1 hour at 4° C. The tissues were obtained from the liver, spleen and muscle of
normal mice. They were chopped with scissors and 1 ml. saline was added to
each gram oftissue before homogenization in a Virtis homogenizer. The complete
absorption of mouse species-specific antibodies in sheep antisera was determined
by Ouchterlony double diffusion test against EAT extract and mouse normal tissue
extract before and after absorption. Two 1-hour absorptions are necessary to
absorb out all anti-mouse tissue antibodies as shown by the double diffusion test.
Preparation ofIgGl and IgG2 immunoglobulins
The absorbed sheep antiserum was treated with 2 volumes of 27 % (W/v)
sodium sulphate and maintained at 370 C. overnight. The precipitate was collec-
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ted by centrifugation at 4000 r.p.m. for 1 hour at 270 C. on a Servall RC-3 centri-
fuge and redissolved in a minimal volume of normal saline. This reconstituted
crude globulins was then dialysed overnight against 0-O1M phosphate buffer,
pH 7-9. The dialysed solution was applied to a column of diethylaminoethyl
cellulose (Whatman DE 52) previously equilibrated with the same 0OO1M buffer.
Elution was carried out by a linear gradient from OO1M to 0-3M phosphate buffer,
pH 7-9. The protein from each peak was pooled and concentrated by ultra-
filtration according to the method of Chard (1968). Immunoelectrophoresis
was performed to test for the purity and differences in electrophoretic mobility of
these fractions. The first peak contained pure IgG2, subsequent peaks contained
protein of successively increasing electrophoretic mobility. An almost pure IgGI
was eluted offat 0-05M phosphate buffer. Subsequent chromatographic separation
of IgGI and IgG2 globulins was then carried out by stepwise elution using 0OO1M
and 0-05M phosphate buffer pH 7-9 (modified from Reisfeld and Hyslop, 1966).
These two forms of IgG immunoglobulin have been distinguished from IgA
immunoglobulins in sheep serum by Curtain and Anderson (1971).
Estimation ofprotein concentration
The concentration of the antiserum fractions was determined by reading at 2
different wavelengths on u.v. spectrophotometer using Warburg and Christian's
method (1941).
51Cr labelling and cytotoxicity test
51Cr labelling of EAT cells and quantitative titration of whole antiserum and
IgGI and IgG2 fractions were performed according to the method of Wigzell
(1965). The concentrations of the isotope (20 ,uCi/ml.) and the EAT cells (106-
108 cells/ml.) used were within the recommended range.
The absorbed antiserum was inactivated at 56° C. for 30 minutes to destroy
complement. IgGI and IgG2 antibody fractions, after being separated by DEAE
column chromatography, were concentrated by ultrafiltration to one-tenth the
volume ofthe original serum sample for use in the cytotoxicity test.
The complement source was guinea-pig serum absorbed with equal volume of
packed EAT cells for 1 hour at 4° C. and diluted 1: 4.
An aliquot of the 51Cr labelled EAT cells was disrupted by successive freezing
and thawing to obtain complete release of the isotope and the counts obtained
were taken as 100 % dead cells. From this count the cytotoxicity in terms of
percentage dead cells of all other antiserum and antiserum fractions on EAT cells
was calculated.
In order to test whether pretreatment of EAT cells with IgG2 will block the
cytotoxicity effect of IgGI, the 51Cr labelled EAT cells were incubated with IgG2
for 45 minutes at 370 C. At the end ofthis incubation period IgGI and absorbed
guinea-pig complement were added and incubated for a further 45 minutes before
proceeding according to Wigzell's method.
In vivo experiments
Five to ten mice were used in each group. The mice were ear tagged and
weighed before injection of antiserum fractions and EAT cells and at 2-3 day
intervals thereafter. The mean increase in body weight in grams was calculated
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for each group. One group of controls was used in each experiment in which mice
were injected with EAT cells alone. All injections were given by the intra-
peritoneal route.
RESULTS
Cytotoxic effect ofIgGl and IgG2 antiserumfractions on 51Cr labelled EAT cells
Antiserum collectedfromeachimmunization, afterabsorptionandinactivation,
were tested for their cytotoxicity on 51Cr labelled EAT cells. It was found that
antiserum from the first 3 immunizations did not have good cytotoxic effect, but
cytotoxicity increased with further immunizations. Only serum from the last
immunization was used for this work.
TABLE I.-Cytotoxicity ofSheep-Anti-EAT IgG1 and IgG2 on 51Cr Labelled
EAT Cells as Measured by Isotope Release
% dead cells at antibody
dilution of:
None 1:1 1:3 1:9 1:27
Freeze thawed labelled cells . . 100 - -
Labelled cells . . . . 7 - - -
Labelled cells + complement* . . 10
Labelled cells + W.S.t + complement . - 72 40 19 12
Labelled cells + IgG1 + complement . - 69 38 16 15
Labelled cells + IgG2 + complement 9 7 10 10
* Guinea-pig serum absorbed with equal volume ofpacked EAT cells and diluted 1 : 4.
t Absorbed and inactivated sheep-anti-EAT whole serum.
Table I shows that sheep anti-EAT whole serum as well as the IgGI fraction
was cytotoxic to EAT cells in the presence of complement. The cytotoxicity
decreased with increasing dilution of the antiserum and IgGI fraction. IgG2
had no cytotoxic effect.
Pretreatment ofthe 5lCrlabelled EAT cells withIgG2 beforethe addition ofthe
IgGl fraction in the presence of complement produced a slight inhibitory effect
on the cytotoxicity ofIgGl. The effect was, however, small and variable between
experiments.
Protective effect ofIgGI and IgG2 antiserumfractions against EAT growth
Effect ofpreincubating IgGi with EAT cells.-Four groups of mice were each
injected i.p. with 103 EAT cells which had been incubated with varying concen-
trations of the absorbed sheep anti EAT IgGI fraction at 370 C. for 30 minutes.
The concentration ofIgGI used ranged from 0-1 mg. to 2 mg. per mouse. Another
group of mice was injected with 103 EAT cells alone as controls. The mice used
were of the same age and weigh between 23 to 30 g. before injection. All mice
which were protected against tumour growth did not have a body weight increase
ofmore than 7 or 8 g. after 28 days whereas mice with tumours could weigh up to
57 or 58 g. at the end of a month's period. The results are presented in Fig. 1.
Itwasfoundthat 0.1 mg. ofIgGI preincubated with 103EATcellswasnotsufficient
to provide complete protection against tumour growth. At this dose only 3 out
of5 mice were protected. However complete protection was provided with a dose
of 0-25 mg. IgGl or greater when preincubated with 103 EAT cells.
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FiG;. 1.-Effect of preincubating IgG1 with EAT cells on tumour growth. Each curve
represents the mean increase in body weight of5 mice afterinjection. Curve A, 103 EAT cells
only; B, 103 EAT cells preincubated with 0-1 mg. IgG,-3 out of 5 mice protected from
tumour growth; C, 103 EAT cells preincubated with 0-25 mg.IgG1; D, 103 EAT cells pre-
incubated with 1-0 mg. IgG1; E, 103 EAT cells preincubated with 2-0 mg. IgG1.
Effect ofpreincubating IgG2 with EAT cells.-When 103 EAT cells were incuba-
ted with varying doses ofthe absorbed sheep anti-EAT IgG2 ranging from 0.1 mg.
to 2 mg. before injecting intraperitoneally into mice, complete protection was also
observed with doses higher than 0a25 mg. When a dose of0 1mg. IgG2 per mouse
was used, again only partial protection resulted as shown in Fig. 2.
In order to investigate further the protective effects of the antitumour IgGi
and IgG2 antiserum fractions against tumour growth, the following experiments
were performed. All injections were carried out by the intraperitoneal route.
Experiment 1 Injection of IgG2 coated EAT cells followed by IgGI 30 minutes
later.
Experiment 2 Injection of IgGI coated EAT cells followed by IgG2 30 minutes
later.
Experiment 3 Injection of IgG2 half hour before EAT cells followed by IgGl 5
days later.
Experiment 4 Injection of IgGI half hour before EAT cells followed by IgG2 5
days later.
Experiment 5 Initial injection of IgGI or IgG2 immediately after EAT cells
followed bythe same antiserum fraction every otherdayfor 10days.
The results ofExperiments 1 and 2 are shown in Table II. It could be observed
that when varying doses ofIgGl or IgG2 were incubated with 103 EAT cells before
injecting intraperitoneally into mice followed 30 minutes later by a constant dose
of 10 mg. of the other antiserum fractions, 100 % protection was observed in all
groups tested up to 34 days after injection. In the control group when EAT cells
alone were injected all mice died of tumour at around 20 days.
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FIG. 2.-Effect of preincubating IgG2 with EAT cells on tumour growth. Each curve
represents the mean increase in body weight of 5 mice after injection. Curve A, 103 EAT
cells only; B, 103 EAT cells preincubated with 0.1 mg. IgG2;-2 out of 5 mice protected
from tumour growth; C, 103 EAT cells preincubated with 0-25 mg. IgG2; D, 103 EAT cells
preincubated with 1.0 mg. IgG2; E, 103 EAT cells preincubated with 2-0 mg. IgG2.
TABLE II.-Effect ofInjecting the Preincubated IgGa or Ig2 with EAT Cells
Before the Injection ofthe Other Antiserum Fraction on Tumour Growth
Preincubation* of EAT with
antiserum fraction
EAT
103
103
108
103
103
103
103
103
IgG,(mg.)
0.1
0 25
1.0
IgG2(mg.)
0-1
0-25
120
2-0
* Half an hour at 370 C.
Concentration ofantiserum
fraction injected 30 No.
minutes later protected
{ A + from tumour/
IgG,(mg.) IgG2(mg.) No. ofanimals
- - . 0/5
1.0 - * 5/5
1*0 . 5/5
1.0 . 5/5
1*0 . 5/5
- 1.0 . 5/5
- 1.0 . 5/5
1.0 . 5/5
TABLE III.-Effect ofInjecting IgGQ and IgG2 Before and After EAT
Cells on Tumour Growth
Concentration ofIgG, or
IgG2 injected i.p. 30
minutes before EAT cells
IgG,(mg.) IgG2(mg.)
1.*0
- 1-0
- 1-0
0-25
1-0
1-0- * 1.0
* 1.0
EAT
103
103
103
103
103
103
103
Concentration ofIgG1 or
IgG2 injected i.p. 5 days
after EAT cells
IgGL(mg.) IgG2(mg-)
0-25
1*0
2-0
- 0-25
- 0-25
- 1-0
- 2-0
Group
A
B
C
D
E
F
G
H
Group
I
J
K
L
M
N
0
No.
protected
from tumour/
No. ofaaiimals
4/5
2/5
3/5
1/6
3/6
2/5
3/6
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Table III gives the data on Experiment 3 and 4. This table shows that when
antiserum fractions were injected separately by the intraperitoneal route, one anti-
serum fraction injected 30 minutes before the injection of EAT cells and the other
fraction 5 days after the EAT cells, only partial protection was observed. The
number of mice protected from tumour do not seem to correlate with the sequence
of the antiserum fractions injected nor with their concentration.
Experiment 5 showed that immediately after the injection of 103 EAT cells,
repeated i.p. injection of 0.1 mg IgGI every other day for 10 days produced an
initial retardation of the growth of EAT in a group of 10 mice, whereas repeated
treatment with the same dose ofIgG2 did not produce any noticeable effect as
compared to the control group.
DISCUSSION
The contradictory results reported by various workers regarding the cytotoxic
fraction of the immunoglobulin G subclasses may be due to the use of different
tumour host systems and species combinations. Furthermore, the method of
sensitization and such factors as the use of adjuvant, route of injection, doses, the
use ofviable, intact or lyophilized antigens are all decisivefactorsfortheproduction
of different immunoglobulin class of antibodies which may lead to inhibition or
progressive growth of the tumour. Alternately, cellular immunity could also
be evoked and dependent on the method of sensitization used.
The in vitro findings as reported here correlates with the findings of Feinstein
and Hobart (1969) in that using sheep antiserum IgGI is the cytotoxic fraction
andIgG2 has no cytotoxic effect. Furthermore, there are some indications that
the cytotoxicity of the anti-tumour IgGI is slightly reduced when the EAT cells
were pretreated with theIgG2 fraction. These results are consistent with the
findings of Kourilsky and co-workers (1964) that when both IgGI and IgG2
antibody fractions are present, the cytotoxic activity of one is reduced in the
presence of the other due to competition between antibody of these types.
However, the in vivo results appear at first glance to be inconsistent with the
in vitro findings. Whereas IgGI is cytotoxic andIgG2 has no cytotoxic effect
in vitro, both antiserum fractions protected against tumour growth when allowed
to coat the cells by preincubation before injecting intraperitoneally into mice.
This demonstrates without doubt that the mechanisms which effect the fate of the
EAT cells are different in vitro and in vivo presumably due to the difference in
the environment of the tumour cells.
In dealing with in vivo experiments, one has to consider the normal defense
mechanism of the host. In the peritoneal cavity macrophages are capable of
engulfing and destroying tumour cells especially in the presence of specific opsoni-
zing antibody. Under the present serni-in-vivo experimental system, it is to be
expected that the macrophages would be reactive to the antibody coated tumour
cells. The reasons being, firstly, specific antibody irrespective of whether it is
the cytotoxic IgGI or the non-cytotoxic IgG2 would likewise sensitize the tumour
cells to the action of macrophages. Secondly, since the coated tumour cells were
injected into the peritoneal cavity where macrophages are abundant, a high
phagocytic activity ofthe opsonized tumour cells is likely to occur.
In the complete in vivo experiments when the antiserum fractions were injected
before and after the EAT cells, only partial protection was observed. It is to be
reasoned that when an antiserum fraction, cytotoxic or noncytotoxic, is injected
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into the peritoneal cavity, it will be diluted by the peritoneal fluid. Therefore
direct coating ofthe tumour cells by the antibody is not likely to occur to the same
degree as during in vitro incubation. Thus the non-opsonized tumour cells will
not facilitate the action of macrophages. Cells which escape being phagocytosed
will undoubtedly proliferate. Thus when the second antiserum fraction was
injected 5 days after the EAT cells this allows the surviving cells to proliferate and
overwhelm any immunity which may be passively transferred. However, there
is an indication that passive immunity isbeingtransferredbythe specific cytotoxic
antiserum fraction. This could be demonstrated in the experiment in which an
initial retardation of tumour growth was observed when repeated injection of
0.1 mg. of the anti-EAT IgGI fraction was given immediately after the adminis-
tration ofEAT cells for a period of 10 days.
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